Get the Stockscreener App
2.649
3.11%
-0.081
Perspective Therapeutics Inc stock is traded at $2.649, with a volume of 213.12K.
It is down -3.11% in the last 24 hours and down -27.34% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$2.73
Open:
$2.77
24h Volume:
213.12K
Relative Volume:
0.21
Market Cap:
$197.67M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-15.44
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
-14.68%
1M Performance:
-27.34%
6M Performance:
+3.32%
1Y Performance:
-78.12%
1-Day Range:
$2.66
$2.77
1-Week Range:
$2.60
$3.10
52-Week Range:
$1.60
$12.90
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.6618 | 202.74M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
122.87 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.65 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
357.27 | 136.23B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
89.17 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
80.80 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Can Perspective Therapeutics Inc. stock hit record highs againJuly 2025 Volume & Verified High Yield Trade Plans - newser.com
What downside risks could hit Perspective Therapeutics Inc. (AAJ0) stockJuly 2025 Summary & Daily Price Action Insights - newser.com
Will Perspective Therapeutics Inc. stock split again soon2025 Winners & Losers & High Accuracy Investment Entry Signals - newser.com
Is Perspective Therapeutics Inc. stock a buy before product launches2025 Key Lessons & Free Real-Time Market Sentiment Alerts - newser.com
Can Perspective Therapeutics Inc. stock stage a strong rebound this quarterJuly 2025 Reactions & Daily Profit Focused Screening - newser.com
Tick level data insight on Perspective Therapeutics Inc. volatilityWeekly Market Report & Accurate Intraday Trading Signals - newser.com
Will Perspective Therapeutics Inc. stock benefit from infrastructure spendingSwing Trade & Expert Verified Stock Movement Alerts - newser.com
What margin trends mean for Perspective Therapeutics Inc. stockDay Trade & Free Weekly Watchlist of Top Performers - newser.com
Will Perspective Therapeutics Inc. stock see PE expansionJuly 2025 Sector Moves & High Win Rate Trade Tips - newser.com
Custom watchlist performance reports with Perspective Therapeutics Inc.July 2025 Spike Watch & Safe Entry Point Identification - newser.com
How to track smart money flows in Perspective Therapeutics Inc.2025 Price Momentum & Free Growth Oriented Trading Recommendations - newser.com
Can Perspective Therapeutics Inc. stock withstand sector downturnsMarket Performance Report & Weekly Breakout Opportunity Watchlist - newser.com
How Perspective Therapeutics Inc. stock reacts to inflationary pressuresQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics to Engage with Investors at Upcoming Conferences - Quiver Quantitative
Perspective Therapeutics to Participate in Upcoming November Conferences - The Manila Times
How Perspective Therapeutics Inc. stock performs in interest rate cycles2025 Stock Rankings & Consistent Profit Alerts - newser.com
Perspective (NYSE AMERICAN: CATX) at Truist Nov 6, UBS fireside chat Nov 11 - Stock Titan
Identifying reversal signals in Perspective Therapeutics Inc.Weekly Gains Report & Precise Swing Trade Alerts - newser.com
Can Perspective Therapeutics Inc. recover in the next quarterQuarterly Growth Report & Expert Curated Trade Setups - newser.com
Can Perspective Therapeutics Inc. stock sustain margin levelsJuly 2025 Price Swings & Expert Verified Movement Alerts - newser.com
Order flow analysis tools used on Perspective Therapeutics Inc.Buy Signal & Accurate Buy Signal Notifications - newser.com
Analyzing recovery setups for Perspective Therapeutics Inc. investors2025 Momentum Check & Safe Capital Preservation Plans - newser.com
Will Perspective Therapeutics Inc. (AAJ0) stock profit from automation waveFed Meeting & Target Return Focused Stock Picks - newser.com
Perspective Therapeutics Advances Cancer Treatment with Innovative Clinical Study - TipRanks
How Perspective Therapeutics Inc. (AAJ0) stock valuation compares with sectorEarnings Growth Report & Safe Entry Zone Identification - newser.com
Perspective Therapeutics Inc. recovery potential after sell offQuarterly Market Summary & Risk Managed Investment Strategies - newser.com
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
0.36%
Cap:
|
Volume (24h):